Delcath Systems (NASDAQ:DCTH) Issues Earnings Results

Delcath Systems (NASDAQ:DCTH) released its earnings results on Monday. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12), RTT News reports. Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. The business had revenue of $7.77 million for the quarter, compared to analyst estimates of $5.00 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share.

Delcath Systems Price Performance

NASDAQ:DCTH traded down $0.12 during trading hours on Wednesday, reaching $7.79. 315,770 shares of the stock were exchanged, compared to its average volume of 247,223. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $9.18. The firm has a 50 day moving average of $7.82 and a 200 day moving average of $6.01. The stock has a market cap of $216.45 million, a PE ratio of -2.90 and a beta of 0.64.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DCTH. Craig Hallum began coverage on shares of Delcath Systems in a research report on Friday, June 28th. They set a “buy” rating and a $18.00 target price on the stock. Stephens reaffirmed an “overweight” rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Delcath Systems in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Delcath Systems has a consensus rating of “Moderate Buy” and an average price target of $19.83.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.